Tuesday, April 5, 2022 ( 3:30 pm - 5 pm CEST)

Rare diseases in the new european pharmaceutical legislation – impacts on patients and healthcare systems 

,
Daniela Bianco
Partner, The European House - Ambrosetti
Simone Boselli
Public Affairs Director, Eurordis
Enrico Costa
Member of the Committee for Orphan Drugs (COMP), EMA; Director, International Affairs Sector, AIFA
Alessandra Moretti
Member of the Committee on the Environment, Public Health and Food Safety, European Parliament
Guido Rasi
Full Professor of Microbiology, University of Rome Tor Vergata; former Director General, EMA
Luisa Regimenti
Member Committee on the Environment, Public Health and Food Safety, European Parliament
Tina Taube
Director Market Access & OMP Policy Lead, EFPIA

The second meeting in the run-up to the Bio€quity Europe 2022 event will be focused on the European pharmaceutical strategy.  

The meeting is designed to deepen the review of the pharmaceutical strategy in 2022 and, in particular, the evolution of legislation on rare diseases and orphan drugs and the impact on patients and healthcare systems.  

How can research on orphan drugs be encouraged? How can patients' access to treatment be improved? What has current European regulation achieved in the past few years? What are the main points of the revision proposals? How is Italy positioned in this scenario? 

Attenzione!
The meeting has already occurred